Deletion 17p syndrome

Clinical trials for Deletion 17p syndrome explained in plain language.

Never miss a new study

Get alerted when new Deletion 17p syndrome trials appear

Sign up with your email to follow new studies for Deletion 17p syndrome, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot

Disease control Ongoing

Researchers are testing whether a combination of daratumumab, pomalidomide and dexamethasone can help people whose multiple myeloma has come back and carries a genetic change called del(17p). This change, found in about 10% of patients at diagnosis, makes the cancer harder to tre…

Matched conditions: DELETION 17P SYNDROME

Phase 2 • Sponsor: Fondazione EMN Italy Onlus • Aim: Disease control

Last updated Sep 11, 2026 00:00 UTC

Deletion 17p syndrome

Get alerted when new Deletion 17p syndrome trials appear

Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot